Pseudohypoaldosteronism Type I Panel
Use
This test is aimed at individuals who have relevant clinical features and either a confirmed or suspected diagnosis of pseudohypoaldosteronism type I. It is tailored for patients with elevated plasma aldosterone and renin levels, which are characteristic of this condition.
Special Instructions
For those using the Exome Platform, the following specimens are accepted: Blood, DNA, Buccal, Saliva, and Tissue. For the Genome Platform, permissible specimens include Blood and DNA.
Limitations
The test has been validated under CLIA and CAP regulations but has not been cleared or approved by the US FDA. This implies that while the test is performed in a certified laboratory setting, it may not meet all anticipated FDA standards and should be interpreted in light of clinical findings and other diagnostic tests.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
2-3 weeks
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided